SLDB – solid biosciences inc. (US:NASDAQ)

News

Solid Biosciences (SLDB) was downgraded by Wall Street Zen from "hold
Solid Biosciences to Participate at Upcoming Investor Conferences
Rett Syndrome Research Trust Appoints Genevieve Laforet, MD, PhD as Chief Medical Officer, Strengthening Leadership in Genetic Medicine Development
Solid Biosciences (SLDB) was upgraded by Truist Financial Corporation to "strong-buy".
Solid Biosciences (SLDB) had its price target raised by JPMorgan Chase & Co. from $11.00 to $12.00. They now have an "overweight" rating on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com